Kiromic BioPharma, Inc. Logo

Kiromic BioPharma, Inc.

KRBP

(1.8)
Stock Price

0,95 USD

-176.06% ROA

337.72% ROE

-0.08x PER

Market Cap.

1.824.186,00 USD

-258.59% DER

0% Yield

0% NPM

Kiromic BioPharma, Inc. Stock Analysis

Kiromic BioPharma, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kiromic BioPharma, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (710.87%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.04x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-161%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 ROA

The stock's ROA (-259.67%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Kiromic BioPharma, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kiromic BioPharma, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Kiromic BioPharma, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kiromic BioPharma, Inc. Revenue
Year Revenue Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kiromic BioPharma, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 1.424.900
2019 1.201.700 -18.57%
2020 5.052.900 76.22%
2021 11.367.800 55.55%
2022 13.920.400 18.34%
2023 10.708.800 -29.99%
2023 9.624.900 -11.26%
2024 16.540.000 41.81%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kiromic BioPharma, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 1.757.700
2019 2.503.700 29.8%
2020 14.144.000 82.3%
2021 13.937.900 -1.48%
2022 17.193.900 18.94%
2023 11.498.000 -49.54%
2023 10.314.400 -11.48%
2024 8.872.000 -16.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kiromic BioPharma, Inc. EBITDA
Year EBITDA Growth
2018 -3.101.700
2019 -3.617.900 14.27%
2020 -18.996.900 80.96%
2021 -24.782.500 23.35%
2022 -29.440.900 15.82%
2023 -12.798.400 -130.04%
2023 -17.143.400 25.35%
2024 -23.184.000 26.06%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kiromic BioPharma, Inc. Gross Profit
Year Gross Profit Growth
2018 -80.900
2019 -87.500 7.54%
2020 -200.000 56.25%
2021 -469.800 57.43%
2022 -2.067.600 77.28%
2023 0 0%
2023 -2.795.900 100%
2024 -2.228.000 -25.49%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kiromic BioPharma, Inc. Net Profit
Year Net Profit Growth
2018 -3.815.700
2019 -3.750.400 -1.74%
2020 -19.203.500 80.47%
2021 -25.654.300 25.15%
2022 -38.181.200 32.81%
2023 -16.774.000 -127.62%
2023 -21.294.000 21.23%
2024 -27.644.000 22.97%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kiromic BioPharma, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -32
2019 -29 -10.34%
2020 -128 77.17%
2021 -67 -89.55%
2022 -70 4.29%
2023 -14 -400%
2023 -19 26.32%
2024 -18 -5.56%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kiromic BioPharma, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -2.290.200
2019 -3.216.600 28.8%
2020 -7.584.200 57.59%
2021 -22.216.300 65.86%
2022 -28.626.400 22.39%
2023 -21.431.900 -33.57%
2023 -5.326.700 -302.35%
2024 -8.278.000 35.65%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kiromic BioPharma, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -2.152.900
2019 -2.913.900 26.12%
2020 -6.126.600 52.44%
2021 -20.321.500 69.85%
2022 -23.745.900 14.42%
2023 -21.225.300 -11.88%
2023 -5.229.200 -305.9%
2024 -8.180.000 36.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kiromic BioPharma, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 137.300
2019 302.700 54.64%
2020 1.457.600 79.23%
2021 1.894.800 23.07%
2022 4.880.500 61.18%
2023 206.600 -2262.29%
2023 97.500 -111.9%
2024 98.000 0.51%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kiromic BioPharma, Inc. Equity
Year Equity Growth
2018 265.300
2019 1.979.000 86.59%
2020 11.362.100 82.58%
2021 27.319.800 58.41%
2022 -5.774.700 573.09%
2023 -9.120.800 36.69%
2023 -4.487.400 -103.25%
2024 -5.170.000 13.2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kiromic BioPharma, Inc. Assets
Year Assets Growth
2018 876.000
2019 2.652.700 66.98%
2020 12.829.700 79.32%
2021 30.729.600 58.25%
2022 11.967.500 -156.78%
2023 12.169.000 1.66%
2023 14.233.500 14.5%
2024 12.464.000 -14.2%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kiromic BioPharma, Inc. Liabilities
Year Liabilities Growth
2018 610.700
2019 673.700 9.35%
2020 1.467.600 54.1%
2021 3.409.800 56.96%
2022 17.742.200 80.78%
2023 21.289.800 16.66%
2023 18.720.900 -13.72%
2024 17.634.000 -6.16%

Kiromic BioPharma, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-14.57
Price to Earning Ratio
-0.08x
Price To Sales Ratio
0x
POCF Ratio
-0.07
PFCF Ratio
-0.07
Price to Book Ratio
-0.34
EV to Sales
0
EV Over EBITDA
-0.63
EV to Operating CashFlow
-0.45
EV to FreeCashFlow
-0.44
Earnings Yield
-12.35
FreeCashFlow Yield
-13.62
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
33.55
Graham NetNet
-8.93

Income Statement Metrics

Net Income per Share
-14.57
Income Quality
1.12
ROE
3.38
Return On Assets
-1.76
Return On Capital Employed
4.86
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
0
Effective Tax Rate
-0.17

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.07
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-16.28
Free CashFlow per Share
-16.49
Capex to Operating CashFlow
-0.01
Capex to Revenue
0
Capex to Depreciation
0.15
Return on Invested Capital
-3.18
Return on Tangible Assets
-1.76
Days Sales Outstanding
0
Days Payables Outstanding
259.78
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
1.41
Inventory Turnover
0
Capex per Share
0.22

Balance Sheet

Cash per Share
2,77
Book Value per Share
-3,43
Tangible Book Value per Share
-3.43
Shareholders Equity per Share
-3.43
Interest Debt per Share
9.51
Debt to Equity
-2.59
Debt to Assets
1.07
Net Debt to EBITDA
-0.52
Current Ratio
0.35
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-4614000
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
7.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kiromic BioPharma, Inc. Dividends
Year Dividends Growth

Kiromic BioPharma, Inc. Profile

About Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

CEO
Mr. Pietro Bersani CPA, J.D.
Employee
35
Address
7707 Fannin
Houston, 77054

Kiromic BioPharma, Inc. Executives & BODs

Kiromic BioPharma, Inc. Executives & BODs
# Name Age
1 Dr. Leonardo Mirandola Ph.D.
Chief Scientific Officer & Interim Chief Operating Officer
70
2 Mr. Pietro Bersani CPA, J.D.
Chief Executive Officer & Director
70
3 Mr. Brian Hungerford CPA, CGMA
Chief Financial Officer
70
4 Dr. Scott Dahlbeck M.D., Pharm.D., PharmD
Chief of Staff
70

Kiromic BioPharma, Inc. Competitors